Drug intelligence / Profile preview

GO-013

Development stage: Preclinical
Lead developer: LigaChem Biosciences, Inc.
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GO-013 (also known as LCB22A or GO-L100) is a preclinical-stage antibody-drug conjugate (ADC) being developed by GO Therapeutics in collaboration with LigaChem Biosciences. It specifically targets Tn-glycopeptides on a breast cancer-specific O-glycoprotein. The ADC utilizes LigaChem's proprietary ConjuAll technology to deliver a monomethyl auristatin E (MMAE) payload. GO-013 is designed to treat various subtypes of breast cancer, including triple-negative breast cancer (TNBC), estrogen receptor-negative (ER-) breast cancer, and metastatic disease, by leveraging the tumor-specific expression of truncated O-glycans (Tn antigens).

Targets

TUBB (Tubulin (alpha and beta subunits))Tn-GP (Tn-glycopeptide epitope)

Beyond the preview

Go deeper on GO-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO-013.

Explore the full profile